Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Viga recall

This article was originally published in The Tan Sheet

Executive Summary

Consumers warned not to take Viga and Viga for Women tablets due to contamination with drug ingredient sildenafil (Pfizer's Viagra), according to June 27 MedWatch safety alert. Products are distributed by Health Nutrition (RMA Labs). Similar recall was announced earlier this month (1"The Tan Sheet" June 2, 2003, In Brief)...

You may also be interested in...

Rhymes with Viagra

Mass-spectrometry analysis shows sildenafil (Pfizer's Viagra) contamination in samples of "100% Natural" erectile dysfunction supplement Niagra Actra-Rx and Actra-Rx from Body Basics, Alberto Sabucedo, PhD, chemist for the International Forensic Research Institute, et al. report in a research letter published in JAMA Feb. 4. Products contained an average of 55 mg per pill, authors say. Niagra is not the first sexual function supplement product found to contain sildenafil (1"The Tan Sheet" June 30, 2003, In Brief and 2"The Tan Sheet" April 14, 2003, p. 6)...

Viga recall

Best Life International announces May 23 it is recalling its Viga supplements due to contamination with sildenafil (Pfizer's Viagra), which FDA notes in same-day 1statement can cause "profound and life-threatening lowering of blood pressure" when taken with nitrates. Product, which is promoted as "increasing desire, confidence and sexual performance," is sold in 30-count bottles. The Mayaguez, Puerto Rico-based firm was involved in a recall of Ancom Anti-Hypertensive Compound tablets earlier this year (2"The Tan Sheet" May 5, 2003, p. 17)...

Roche's Innovative Drug Engine ‘Firing On All Cylinders’

Roche’s Q1 update highlighted some key coming drug catalysts and early stage clinical efforts, including those for a potential COVID pill and for targeted cancer vaccines.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts